These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33467114)

  • 41. Combining serum uric acid and fatty liver index to improve prediction quality of nonalcoholic fatty liver disease.
    Ding Y; Tang Z; Wang M; Wang M; Zhang R; Zhang L; Zhang M; Guan Q; Wang J
    Saudi J Gastroenterol; 2023; 29(3):191-198. PubMed ID: 36876619
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease.
    Subasi CF; Aykut UE; Yilmaz Y
    Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):137-41. PubMed ID: 25486027
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat Using a New Quantitative Ultrasound Technique.
    Lin SC; Heba E; Wolfson T; Ang B; Gamst A; Han A; Erdman JW; O'Brien WD; Andre MP; Sirlin CB; Loomba R
    Clin Gastroenterol Hepatol; 2015 Jul; 13(7):1337-1345.e6. PubMed ID: 25478922
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Validation study of systems for noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in Latin population.
    Pérez-Gutiérrez OZ; Hernández-Rocha C; Candia-Balboa RA; Arrese MA; Benítez C; Brizuela-Alcántara DC; Méndez-Sánchez N; Uribe M; Chávez-Tapia NC
    Ann Hepatol; 2013; 12(3):416-24. PubMed ID: 23619258
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prediction of Cardiovascular Risk Using Nonalcoholic Fatty Liver Disease Scoring Systems.
    Kweon YN; Ko HJ; Kim AS; Choi HI; Song JE; Park JY; Kim SM; Hong HE; Min KJ
    Healthcare (Basel); 2021 Jul; 9(7):. PubMed ID: 34356275
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High FIB-4 index as an independent risk factor of prevalent chronic kidney disease in patients with nonalcoholic fatty liver disease.
    Xu HW; Hsu YC; Chang CH; Wei KL; Lin CL
    Hepatol Int; 2016 Mar; 10(2):340-6. PubMed ID: 26676626
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diagnostic accuracy of a noninvasive hepatic ultrasound score for non-alcoholic fatty liver disease (NAFLD) in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).
    Goulart AC; Oliveira IR; Alencar AP; Santos MS; Santos IS; Martines BM; Meireles DP; Martines JA; Misciagna G; Benseñor IM; Lotufo PA
    Sao Paulo Med J; 2015; 133(2):115-24. PubMed ID: 26018881
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnostic value of alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) index combined with γ-glutamyl transferase in differentiating ALD and NAFLD.
    Wang J; Li P; Jiang Z; Yang Q; Mi Y; Liu Y; Shi R; Zhou Y; Wang J; Lu W; Li S; Liu D
    Korean J Intern Med; 2016 May; 31(3):479-87. PubMed ID: 27025268
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease.
    Motamed N; Sohrabi M; Ajdarkosh H; Hemmasi G; Maadi M; Sayeedian FS; Pirzad R; Abedi K; Aghapour S; Fallahnezhad M; Zamani F
    World J Gastroenterol; 2016 Mar; 22(10):3023-30. PubMed ID: 26973398
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Study of reactive oxygen species and adiponectin for chronic HBV infection combined with nonalcoholic fatty liver diseases].
    Xu L; Zhong Y; Su ST; Liu YG; Lyu FN; Zhou XL; Ren JQ; Li P; Shi RF; Jiang Y; Fan JG; Mi YQ
    Zhonghua Gan Zang Bing Za Zhi; 2020 Mar; 28(3):247-253. PubMed ID: 32306658
    [No Abstract]   [Full Text] [Related]  

  • 51. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease.
    Yang M; Jiang L; Wang Y; Li X; Zou Z; Han T; Nan Y; Lu F; Zhao J
    J Gastrointestin Liver Dis; 2019 Sep; 28(3):289-296. PubMed ID: 31517325
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: A meta-analysis study.
    Sun W; Cui H; Li N; Wei Y; Lai S; Yang Y; Yin X; Chen DF
    Hepatol Res; 2016 Aug; 46(9):862-70. PubMed ID: 26763834
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
    Lemoine M; Assoumou L; De Wit S; Girard PM; Valantin MA; Katlama C; Necsoi C; Campa P; Huefner AD; Schulze Zur Wiesch J; Rougier H; Bastard JP; Stocker H; Mauss S; Serfaty L; Ratziu V; Menu Y; Schlue J; Behrens G; Bedossa P; Capeau J; Ingiliz P; Costagliola D;
    J Acquir Immune Defic Syndr; 2019 Apr; 80(4):e86-e94. PubMed ID: 30570529
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 57. The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 1 diabetic patients.
    Singh A; Le P; Lopez R; Alkhouri N
    Hepatol Int; 2018 Jan; 12(1):37-43. PubMed ID: 29318450
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diagnostic ability using fatty liver and metabolic markers for metabolic-associated fatty liver disease stratified by metabolic/glycemic abnormalities.
    Okada A; Yamada G; Kimura T; Hagiwara Y; Yamaguchi S; Kurakawa KI; Nangaku M; Yamauchi T; Matsuyama Y; Kadowaki T
    J Diabetes Investig; 2023 Mar; 14(3):463-478. PubMed ID: 36566480
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Validation of five hepatic steatosis algorithms in metabolic-associated fatty liver disease: A population based study.
    Liu Y; Liu S; Huang J; Zhu Y; Lin S
    J Gastroenterol Hepatol; 2022 May; 37(5):938-945. PubMed ID: 35174539
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Performance of Fatty Liver Index in Identifying Non-Alcoholic Fatty Liver Disease in Population Studies. A Meta-Analysis.
    Castellana M; Donghia R; Guerra V; Procino F; Lampignano L; Castellana F; Zupo R; Sardone R; De Pergola G; Romanelli F; Trimboli P; Giannelli G
    J Clin Med; 2021 Apr; 10(9):. PubMed ID: 33925992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.